Symposium 5

February 1, 2011

07.00-08.45 hr

Registration

09.00 hr

 

 

Inauguration ceremony

Keynote Address
A Nobel Prize by Chance!

Prof. (Dr.) Rolf Zinkernagel
Nobel Laureate ( Medicine )
Zurich, Switzerland

11.00 hr

Tea/Coffee Break

Session I

Chairperson

Dr. Kapil Dhingra
Retired Vice President, Head, Oncology Disease Biology Leadership Team, Roche

Dr. Y. K. Gupta
Professor & Head, Dept of Pharmacology, All India Institute of Medical Sciences, Delhi, India

12.00 hr

 

Therapeutic Science and Medicine: New Models for Academic--Industry Interactions

Dr. William W. Chin, MD, PhD
Executive Dean for Research
Professor of Medicine
Harvard Medical School
Retired Senior Vice President, Discovery Research & Clinical Investigation, Eli Lilly, USA

12.45 hr

 

State of Oncology Therapeutic Research : A look ahead

Dr. Kapil Dhingra
Retired Vice President, Head, Oncology Disease Biology Leadership Team, Roche

13.10 hr

Lunch break / Poster Session

14.30 hr

 

Synthetic Lethality in Cancer Treatment: Current status of PARP Inhibitors

Dr. Hilary Calvert, MD
Director of Cancer Drug Discovery and Development,
UCL Cancer Institute, London, UK

15.15 hr

 

DNA repair dysfunctionality in lung cancer

Dr. Jean-Charles Soria, MD
Institut Gustave Roussy,
Head of the Early Therapeutics Innovations Service (SITEP), Villejuif, France

16.00 hr

Tea/Coffee Break

16.30 hr

Outliers, Invisible Gorillas, and Fellow Travelers-Understanding the Difference for Molecularly Targeted Drug Development

Dr. Anthony W. Tolcher, MD
Director of START (South Texas Accelerated Research Therapeutics) and Clinical Professor of Medicine in the Division of Medical Oncology, University of Texas Health Science Center, San Antonio, USA

17.15 hr

 

PI3 Kinase inhibitor for the treatment of cancer

Dr. Pablo Cagnoni, MD
SVP Global Head, Clinical Development,
Novartis Pharmaceuticals, Switzerland

18.00 hr

Panel Discussion

  • Dr. Kapil Dhingra
  • Dr. Rolf Zinkernagel
  • Dr. William W. Chin
  • Dr. Hilary Calvert
  • Dr. Jean-Charles Soria
  • Dr. Anthony W. Tolcher
  • Dr. Pablo Cagnoni

 

February 2, 2011

Session II

Chairperson

Dr. Hilary Calvert, MD
Director of Cancer Drug Discovery and Development,
UCL Cancer Institute, London, UK

Dr. S. D. Seth
Advisor, Indian Council of Medical Research

09.00 hr

 

Harnessing the immune system to treat cancer – A reality at last

Dr. Kapil Dhingra
Retired Vice President, Head, Oncology Disease Biology Leadership Team, Roche

09.45 hr

 

Manipulating the Inhibitory Arm of the Immune System, a Needed Strategy for Cancer Therapy

Dr. Samir N. Khleif, M.D.
Head, Cancer Vaccine Section, Investigator, National Cancer Institute
Bethesda, USA

10.30 hr

 

T cell-engaging BiTE antibodies for cancer therapy

Dr. Patrick Baeuerle, PhD
Chief Scientific Officer,
Micromet

11.15 hr

Tea/Coffee Break

11.45 hr

 

Oncology Clinical Research : India

Prof. Vinod Raina, MD, FRCP.
Head Dept of Medical Oncology &
Head Delhi Cancer Registry
Institute of Rotary Cancer Hospital
All India Institute of Medical Sciences (AIIMS)

12.30 hr

 

Targeting Multiple Myeloma: Use of Translational Research to Inform a Development Path for the KSP inhibitor ARRY-520

Dr. Duncan Walker, PhD
Senior Director, Translational Medicine, Array Biopharma, USA

13.15 hr

Lunch Break / Poster Session

Session III

Chairperson

Dr. Pankaj Shah
Director, Gujarat Cancer Research Institute

Dr. J. S. Yadav
Director, Indian Institute of Chemical Technology

15.00 hr

 

Estrogen receptor beta-selective compounds and their potential role in cancer therapy

Anneli Hallgren
CSO, Karobio
Sweden

15.45 hr

Cancer Metabolism:  The Warburg Effect Revisited

Dr. Rajesh Chopra MD, PhD
Vice President Translational Development, Celgene, USA

16.30 hr

Tea/Coffee Break

17.00 hr

 

From Fragment to clinic: Translational biomarkers for clinical candidates derived from fragment-based drug design.

Dr. John Lyons, MSc PhD,
VP Translational Research & Development,
Astex Pharma

17.45 hr

 

'Innovation management in drug discovery'

Dr. Mikio Arisawa
Retd. Head of Discovery,
Chugai (Roche Group), Japan

18.30 hr

Panel discussion

  • Dr. Kapil Dhingra
  • Dr. Samir N. Khleif
  • Dr. Patrick Beauerle
  • Dr. Anneli Hallgren
  • Dr. Duncan Walker
  • Dr. Rajesh Chopra
  • Dr. Mikio Arisawa
  • Dr. Vinod Raina

19.00 hr

Workshop by Cambridgesoft Corp.
Informatics solution for Research,
Cambridgesoft Corp, USA

19.30 hr

Workshop by Biotron Healthcare
HTRF chemistry and applications in drug discovery
Roderick Haroutunian, CIS BIO, France

BMG omega / PHERAstar: new standard for multi lable detection
John Abbenante, BMG Lab Tech Australia

20.00 hr Workshop by GE Healthcare
Modern Bioanalytics- Getting closer to understanding your product
Mr. Lalith Kishore, GE Healthcare

 

February 3, 2011

Session IV

Chairperson

Dr. Richard DiMarchi, PhD
Gill Professor of Biochemistry, Indiana University, USA

Dr. John Amatruda, MD,
Retired Merck Sr. VP & Franchise Head, Diabetes/Obesity, USA

09.00 hr

 

New Therapies for the Treatment of Type II Diabetes:  Challenges and Opportunities

Nancy Thornberry
Sr. VP, Metabolic Franchise Head, Merck Research Labs, USA

09.45 hr

 

CNS Integration of Systems Metabolism: Target Opportunities for Diabetes Prevention and Therapy

Dr. Matthias Tschoep, MD
Professor of Endocrinology, University of Cincinnati, USA

10.30 hr

Tea/Coffee Break

11.00 hr

 

MicroRNAs: Function in metabolism and therapeutic opportunities

Dr. Markus Stoffel, MD
Professor, ETH Zurich Institute of Molecular Systems Biology Zurich, Switzerland

11.45 hr

 

Insights into insulin resistance from metabolomics analysis following bariatric surgery

Dr. Charles Burant, MD, PhD
Atkins Professor of Metabolism, University of Michigan, USA

12.30 hr

Lunch Break / Poster session 

Session V

Chairperson

Nancy Thornberry
Sr. VP, Metabolic Franchise Head, Merck Research Labs, USA

Dr. Gianni Gromo
Sr. VP and Global Head, Metabolic & Vascular Disease Area, Roche, Switzerland

14.00 hr

 

Dissecting Hypothalamic Signaling: Targeting Metabolic Disease

Dr. Jens C. Bruning, MD
Institute of Genetics, University of Cologene, Germany

14.45 hr

 

The dynamic interaction between food, brain and body mass index

Dr. Dana Small, PhD
Associate Professor, Department of Psychiatry Yale University School of Medicine and Associate Fellow, The John B Pierce Laboratory, USA

15.30 hr Tea/Coffee Break / Poster Session
16.00 hr  

ZYOG1: A Novel Oral GLP-1 agonist for treatment of Type 2 Diabetes

Dr. Mukul R. Jain, PhD
Sr. VP, Zydus Research Center, Ahmedabad, India

16.45 hr  

Structure-based design of biotherapeutics with enhanced solubility and bio-stability

Dr. Faming Zhang, PhD
CEO, Waterstone Pharmaceuticals Inc., USA.

17.30 hr  

Expectations of India from global scientific community

Dr. V. M. Katoch
Secretary, Department of Health Research, Government of India &
Director-General, Indian Council of Medical Research, India

17.50 hr

Panel Discussion

  • Dr. Richard DiMarchi
  • Nancy Thornberry
  • Dr. Matthias Tschoep
  • Dr. Markus Stoffel
  • Dr. Charles Burant
  • Dr. Jens C. Bruning
  • Dr. Dana Small
  • Dr. Mukul R. Jain
  • Dr. Faming Zhang
  • Dr. V. M. Katoch

19.00 hr

Cultural Program

Venue : Hotel Courtyard Marriot
Ramdev Nagar Cross Roads, Satellite, Ahmedabad

 

February 4, 2011

Session VI

Chairperson

Dr. Charles Burant, MD, PhD
Atkins Professor of Metabolism, University of Michigan, USA

Dr. T. K. Chakraborty
Director, Central Drug Research Institute

09.00 hr

 

The past, present and the future of Cardiovascular  translational medicine research

Dr. Gianni Gromo
Sr. VP and Global Head, Metabolic & Vascular Disease Area, Roche, Switzerland

09.45 hr

 

Should Safety, Drug Exposure and Clinical Efficacy of Diabetes Drugs Be Assessed in Patients or in Healthy Volunteers?


Dr. Marcus Hompesch,
President - CEO
Profil Institute for Clinical Research Inc.
California, USA

10.30 hr

 

“A prospective, multi-centric, open-label, single arm study to evaluate the safety and efficacy of 4mg of ZYH1 in hypertriglyceridemia in HIV associated lipodystrophy”

Dr. Dhiraj Gambhire, MD
Cadila Healthcare Ltd, Mumbai, India

11.15 hr

Tea/Coffee Break / Poster Session

11.45 hr

 

Big Pharma: Leveraging for an Efficient R&D Organization

Dr. John Amatruda, MD,
Retired Merck Sr. VP & Franchise Head, Diabetes/Obesity, USA

12.30 hr

 

Development of Prodrug Chemistry Suitable for Application to Therapeutic Peptides

Dr. Richard DiMarchi, PhD
Gill Professor of Biochemistry, Indiana University, USA

Retired Executive VP, Lilly Research Labs., Indianapolis, USA

13.15 hr

Lunch Break

14.30 hr

 

Treatment of Metabolic Diseases with Proteins Site-Specifically Optimized for Pharmacological Use

Dr. Douglas W. Axelrod, MD, PhD
Chief Medical Officer
Senior Vice President, Development
Ambrx, Inc.

15.15 hr

 

Liver Selective Glucokinase Activation for Treating Type 2 Diabetes: Translation from Mouse to Man


Kasim A. Mookhtiar, Ph.D.
Chief Scientific Officer and EVP, Drug Discovery
Advinus Therapeutics Pvt Ltd, Pune, India

16.00 hr

Panel Discussion

  • Dr. Richard DiMarchi
  • Dr. John Amatruda
  • Dr. Gianni Gromo
  • Dr. Marcus Hompesch
  • Dr. Douglas W. Axelrod
  • Dr. Kasim A. Mookhtiar

16.30 hr

 

 

Best Posters Award
  • Three selected posters will be announced for prize presentation.
  • Time of 10 mins each will be provided to the 3 best posters for podium presentation.

17.00 hr

Wrap-up session

 

 

Home Contact Us Life-sciences Exhibition